Simone Michelan-Duarte

Simone Michelan-Duarte

Auto-generated profile, based on publicly available information

Simone Michelan-Duarte

Laboratory of Medicinal and Computational Chemistry - Sao Carlos Institute of Physics, University of Sao Paulo, Sao Carlos, Brazil

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 April 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
TIThe Brazilian Reproducibility Initiative
The Brazilian Reproducibility Initiative
OAOlavo Bohrer Amaral
Olavo Bohrer Amaral
CCClarissa França Dias Carneiro
Clarissa França Dias Carneiro
KNKleber Neves
Kleber Neves
ASAna Paula Wasilewska Sampaio
Ana Paula Wasilewska Sampaio
WAWanessa Fernanda Altei
Wanessa Fernanda Altei
Concerns over the replicability and reproducibility of published research have grown in many research fields, but empirical data to inform policies are still scarce. Biomedical research in Brazil expanded rapidly over the last three decades, with no systematic assessment of the replicability of its findings. With this in mind, we set up the Brazilian Reproducibility Initiative, a multicenter replication of published experiments from Brazilian science using three common experimental methods: the MTT assay, the reverse transcription polymerase chain reaction (RT-PCR) and the elevated plus maze (EPM). A total of 56 laboratories performed 143 replications of 56 experiments; of these, 90 replications of 45 experiments were considered valid by an independent committee. Replication rates for these experiments varied between 20 and 44% according to five predefined criteria. In median terms, ratios between group means were 58% lower in replications than in original experiments, while coefficients of variation were 82% higher. Effect size decrease was smaller for MTT experiments, original results with less variability and those considered more challenging to replicate, while t values for replications were positively correlated with researcher predictions about replicability, and negatively correlated with the rate of publications by the original article’s last author. Deviations from preregistered protocols were very common in replications, most frequently due to reasons inherent to the experimental model or related to infrastructure and logistics. Our results highlight factors that limit the replicability of results published by researchers in Brazil and suggest ways by which this scenario can be improved.

28 October 2021 in Future Medicinal Chemistry
Verified
Journal Article
Closed access
AOAldo Oliveira
Aldo Oliveira
LMLucas dos S Mello
Lucas dos S Mello
COCamila H Ogihara
Camila H Ogihara
TDThiago H Döring
Thiago H Döring
DPDavid L Palomino-Salcedo
David L Palomino-Salcedo
AAAdriano Andricopulo
Adriano Andricopulo
Background: Schiff bases are synthetically accessible compounds that have been used in medicinal chemistry. Methods & results: In this work, 27 Schiff bases derived from diaminomaleonitrile were sy... Graphical abstract

31 March 2025 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
RORamon Guerra de Oliveira
Ramon Guerra de Oliveira
LCLuiza R. Cruz
Luiza R. Cruz
MDMarco A. Dessoy
Marco A. Dessoy
PKPaul J. Koovits
Paul J. Koovits
DSDeborah A. dos Santos
Deborah A. dos Santos
LDLuiz C. Dias
Luiz C. Dias
Chagas disease (CD), caused by the flagellate protozoan Trypanosoma cruzi, is a neglected tropical disease endemic in 21 countries. The only two antiparasitic drugs approved for its treatment, benznidazole and nifurtimox, have significant drawbacks. We present herein the optimization of a series of substituted indoles that were identified through phenotypic screening against T. cruzi. Early lead compounds with balanced potency and physicochemical properties were advanced to animal studies but showed limited plasma exposure. Medicinal chemistry strategies were used to improve metabolic stability and solubility, but unfortunately, this effort failed to yield compounds with improvements in both exposure and potency. Still, the best compound was progressed for a proof-of-concept efficacy study using acute and chronic mice models of Chagas disease. Despite showing antiparasitic activity in these in vivo studies, the optimization work with this series was stopped due to unfavorable drug metabolism and pharmacokinetic (DMPK) properties and a deprioritized mechanism of action (CYP51 inhibition).

27 August 2024 in ChemMedChem
Verified
Journal Article
Closed access
RERocío Marisol Espinoza‐Chávez
Rocío Marisol Espinoza‐Chávez
celso de oliveira Rezende Júniorcelso de oliveira Rezende Júnior
celso de oliveira Rezende Júnior
MSMariana Laureano de Souza
Mariana Laureano de Souza
RCRafael Consolin Chelucci
Rafael Consolin Chelucci
SMSimone Michelan‐Duarte
Simone Michelan‐Duarte
LDLuiz Carlos Dias
Luiz Carlos Dias